|
| Press Releases |
|
 |
|
| Monday, September 8, 2025 |
|
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. more info >> |
|
| Thursday, September 4, 2025 |
|
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
| Wednesday, September 3, 2025 |
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, September 1, 2025 |
|
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
| Friday, August 29, 2025 |
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Monday, August 25, 2025 |
|
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
| Monday, August 18, 2025 |
|
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, July 31, 2025 |
|
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025). more info >> |
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually more info >> |
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 6, 2025 22:44 JST
|
|
|
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia 
Nov 6, 2025 21:30 HKT/SGT
|
|
|
K.Wah Group Supports 2025 Legislative Council Election
Nov 6, 2025 21:09 HKT/SGT
|
|
|
Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 6, 2025 22:00 JST
|
|
|
Fujitsu to develop new chatbot for Japan Pension Service
Nov 6, 2025 21:24 JST
|
|
|
The 17th Hong Kong International Wine & Spirits Fair Opens Today
Nov 6, 2025 19:16 HKT/SGT
|
|
|
Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 6, 2025 17:30 JST
|
|
|
Excent Capital Announces Swap-Free Trading on All U.S. Stocks and Indices
Nov 6, 2025 16:00 HKT/SGT
|
|
|
ESA, MediaTek, Eutelsat, Airbus, Sharp, ITRI, and R&S Announce World's First Rel-19 5G-Advanced NR-NTN Connection over OneWeb LEO Satellites
Nov 6, 2025 17:00 JST
|
|
|
Hybrid Dump Truck Demonstration Test at South African Mining Site Selected by UNIDO's Industrial Cooperation Programme
Nov 6, 2025 16:16 JST
|
|
|
Mitsubishi Power Receives Contract to Upgrade Existing Boiler Equipment at the O Mon 1 Thermal Power Plant in Vietnam
Nov 6, 2025 16:01 JST
|
|
|
Tune Talk partners with Truecaller to Enhance Customer Experience and Trust Across Malaysia's Telecom Sector
Nov 6, 2025 15:00 HKT/SGT
|
|
|
MHI and ICM Form Strategic Alliance to Advance Ethanol Dehydration Efficiency
Nov 6, 2025 15:38 JST
|
|
|
Telecoms World Asia 2025 Returns To Bangkok to Power Asia's Connected Future
Nov 6, 2025 14:33 HKT/SGT
|
|
|
JCB and Agoda Enter Long-Term Partnership to Enhance Travel and Payment Experience Across Asia
Nov 6, 2025 12:00 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
